Oncology · page 3

Adding venetoclax to DA-EPOCH-R in double-hit lymphoma killed more patients than it saved

ALLIANCE A051701 closed its double-hit cohort early after six of 37 patients died on treatment with venetoclax added, against one of 36 without. Progression-free survival did not improve, and 24-month overall survival was 52% against 72%. Elsewhere, ivonescimab extended progression-free survival in EGFR-mutant lung cancer after TKI failure.